SCHEMBL4658683

SCHEMBL4658683

NC(=O)CC[C@H](N)C(=O)c1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.47
PMP22 Q01453 2/20 0.47
KMT2A Q03164 2/20 0.47
ALOX15 P16050 1/20 0.47
PDPK1 O15530 1/20 0.42
CA2 P00918 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MPO P05164 1/20 0.41
CYP3A4 P08684 1/20 0.41
KDM5A P29375 1/20 0.41
GFER P55789 1/20 0.41
HIF1A Q16665 1/20 0.41
SLC7A5 Q01650 1/20 0.41
LMNA P02545 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ABL1 P00519 1/20 0.40
POLB P06746 1/20 0.40
ALPI P09923 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4658680 1.00 BLM (0.47) BLMPMP22KMT2AALOX15PDPK1
SCHEMBL29634956 0.84 BLM (0.53) BLMPMP22KMT2AALOX15NPC1
SCHEMBL9327656 0.81 BLM (0.47) BLMPMP22PDPK1CA2NPC1
SCHEMBL1970885 0.81 BLM (0.47) BLMPMP22KMT2AALOX15CA2
SCHEMBL7094989 0.81 KDM4E (0.50) BLMPMP22KMT2AALOX15CA2
SCHEMBL7094986 0.81 KDM4E (0.50) BLMPMP22KMT2AALOX15CA2
SCHEMBL2912663 0.78 ESR1 (0.40) BLMPMP22KMT2AALOX15CA2
SCHEMBL8107388 0.78 ESR1 (0.40) BLMPMP22KMT2AALOX15CA2
SCHEMBL2574988 0.76 PDPK1 (0.46) BLMPMP22PDPK1CA2NPC1
SCHEMBL2574989 0.76 PDPK1 (0.46) BLMPMP22PDPK1CA2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-53113032-A None JP disclosed
US-11904014-B2 Immunostimulatory compositions Assistance Publique—Hopitaux de Paris (FR) 2024-02-20 US disclosed
EP-2001854-A2 PHYTONUTRIENT COMPOSITIONS FROM MUSHROOMS OR FILAMENTOUS FUNGI AND METHODS OF USE THE PENN STATE RESEARCH FOUNDATION (US) 2008-12-17 EP disclosed
WO-2007106859-A2 PHYTONUTRIENT COMPOSITIONS FROM MUSHROOMS OR FILAMENTOUS FUNGI AND METHODS OF USE THE PENN STATE RESEARCH FOUNDATION (US) 2007-09-20 WO disclosed
JP-S53113032-A IMMUNE DEPRESANTS MITSUBISHI CHEM IND LTD 1978-10-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11904014-B2 Immunostimulatory compositions CD47, CD74, LY96 BLM 1393/4885PMP22 2639/4885KMT2A 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.